GSK plc Stock Opened Up by 3.02% on Feb 17: Drivers Behind the Movement

GSK’s stock experienced significant upward movement today, driven primarily by a positive regulatory development and a capital allocation announcement. The European Commission granted approval for Exdensur (depemokimab) in two key indications: severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. This marks the fourth regulatory clearance for the drug, following approvals in the United States, United Kingdom, and Japan. Exdensur is notable as the first ultra-long-acting biologic of its kind in the EU for these conditions, and the company projects substantial peak annual sales if it secures approval across all potential indications. This development significantly strengthens GSK's respiratory franchise and expands its potential patient base.

Further contributing to the positive sentiment, GSK also announced the commencement of the fourth tranche of its £2 billion share buyback program. This latest tranche involves repurchasing up to £0.45 billion of ordinary shares, a move intended to return excess capital to shareholders and enhance earnings per share. Such programs typically signal management confidence in the company's financial health and future prospects.

These significant company-specific events coincide with generally favorable financial performance, as GSK recently reported fourth-quarter 2025 earnings that surpassed analyst expectations. The company also provided an optimistic outlook and guidance for 2026, which had already contributed to a positive investor perception earlier in the month. Additionally, new effectiveness data for GSK’s RSV vaccine, Arexvy, showing reductions in certain RSV-related risks, was also released today, further bolstering the positive news flow.

Technically, GSK plc (GSK) shows a MACD (12,26,9) value of [2.13], indicating a buy signal. The RSI at 74.33 suggests buy condition and the Williams %R at -13.36 suggests oversold condition. Please monitor closely.

GSK plc (GSK) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is 43.02B, ranking 13 in the industry. The net profit is 7.53B, ranking 11 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as BUY, with an average price target of 50.11, a high of 67.00, and a low of 35.55.

Company Specific Risks:

• Moderating 2026 revenue guidance of 3–5% indicates a potential slowdown in top-line growth, raising concerns about future financial performance.
• The company faces ongoing market risks from potential faster-than-anticipated fading vaccine demand and increasing pricing pressures in key markets, which could undermine recent share price gains.
• Institutional analyst consensus maintains a "Hold" rating, with some expressing concerns that the stock's current valuation is "stretched," suggesting limited near-term upside potential.